Originally published on Technavio:Antiemetic Drug Market Analysis Across North America, Europe, Asia, and Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2023-2027

The estimated growth of the Global antiemetics drugs market size is USD 1,632.81 million at a compound annual growth rate (CAGR) of 6.47% between 2022 and 2027.

The escalating prevalence of nausea and vomiting stands out as a major driver influencing the market. These common symptoms, occurring in millions of people globally due to various illnesses and treatments, drive the demand for antiemetic drugs. With increasing cancer rates and advancements in cancer treatments, there is a growing number of individuals facing these symptoms.

Segmentation by Application, Drug Class, and Geography Analysis

Chemotherapy

The chemotherapy segment is expected to witness significant market share growth during the forecast period. Chemotherapy drugs effectively eliminate cancer cells but can be harmful to normal cell types, leading to gut-related issues and triggering vomiting centers in the brain. Antiemetic therapy in Chemotherapy-Induced Nausea and Vomiting (CINV) aims to control these symptoms, enabling patients to undergo chemotherapy treatments without interruptions or dose reductions.

Drug Class Analysis

The 5-HT3 receptor antagonists segment is projected to dominate, holding the largest share. These drugs play a crucial role in managing nausea and vomiting by blocking serotonin activity in the gastrointestinal and central nervous systems. Inhibiting the activation of these receptors, 5-HT3 receptor antagonists help reduce the sensation of nausea and the occurrence of vomiting. The growing use of these antagonists is expected to propel segment growth during the forecast period.

Dopamine Antagonists

Dopamine antagonists, another class of drugs for nausea and vomiting management, work by shutting down dopamine receptors in the brain, alleviating associated symptoms. Modulating the effects of dopamine on the chemoreceptor trigger zone (CTZ) and the vomiting center in the brain, these drugs reduce the urge to vomit. Dopamine antagonists are particularly effective in managing postoperative nausea and vomiting (PONV). The increasing use of dopamine antagonists is anticipated to drive segment growth during the forecast period.

To Learn deeper into this report , View Sample PDF

North America is expected to contribute 37% to the global market growth during the forecast period. Analysts at Technavio elaborate on the regional trends and drivers shaping the market. North America, including the US, Canada, and Mexico, is a key region for antiemetic drug development, manufacturing, and consumption. The presence of leading pharmaceutical companies investing in research and development for innovative drugs contributes to the region's market growth.

Vendors are employing various strategies, such as alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to strengthen their market presence. The report provides detailed analyses of the competitive landscape, featuring information about 20 market vendors, including:

For more information please contact.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/